Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma 200Osteosarcoma 74Sarcoma, Ewing 50Rhabdomyosarcoma 48Melanoma 42Neuroblastoma 38Gastrointestinal Stromal Tumors 35Neoplasms 34Neoplasm Metastasis 32Bone Neoplasms 32Colorectal Neoplasms 31Glioblastoma 29Breast Neoplasms 25Ovarian Neoplasms 24Wilms Tumor 23Rhabdoid Tumor 23Gliosarcoma 23Glioma 23Liposarcoma 22Carcinoma, Non-Small-Cell Lung 22Lymphoma, Non-Hodgkin 21Sarcoma, Kaposi 20Neurofibrosarcoma 20Carcinoma, Renal Cell 20Pancreatic Neoplasms 19Medulloblastoma 19Hepatoblastoma 19Desmoid Tumors 18Thyroid Neoplasms 17Lymphoma 17

Interventions

tazemetostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Inhibition, Psychological × Sarcoma × 90 days × Clear all
NCT04917042 2026-06-04

Tazemetostat in Malignant Peripheral Nerve Sheath Tumors

University of Florida

Phase 2 Active not recruiting
10 enrolled 12 charts
Sarcoma

Inhibition, Psychological, Sarcoma, Nerve Sheath Neoplasms, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡